Granisetron to Prevent Nausea and Vomiting After Chemotherapy in Patients With Malignant Disease
A Double-blind, Multicenter, Parallel Study Comparing the Efficacy and Safety of Kytril Tablets With Placebo, in the Prevention of Nausea and Vomiting During the Days Following Administration of IV Cyclophosphamide-based or Carboplatin-based Chemotherapy in Patients With Malignant Disease
Sponsor: Jonsson Comprehensive Cancer Center
Listed as NCT00005024, this PHASE3 trial focuses on Unspecified Adult Solid Tumor, Protocol Specific and remains ongoing. Sponsored by Jonsson Comprehensive Cancer Center, it has been updated 5 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Jonsson Comprehensive Cancer Center
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.